Segall Bryant & Hamill LLC Increases Stock Holdings in Insulet Corporation $PODD

Segall Bryant & Hamill LLC increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 3.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 93,632 shares of the medical instruments supplier’s stock after acquiring an additional 3,300 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Insulet were worth $29,417,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of PODD. Zions Bancorporation National Association UT purchased a new position in Insulet during the 1st quarter worth $26,000. Golden State Wealth Management LLC lifted its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares in the last quarter. SouthState Corp boosted its holdings in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. bought a new stake in Insulet in the 2nd quarter worth about $32,000. Finally, Trust Co. of Toledo NA OH bought a new stake in Insulet in the 2nd quarter worth about $35,000.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. JPMorgan Chase & Co. lifted their price target on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Jefferies Financial Group raised their target price on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Rothschild & Co Redburn lifted their target price on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $379.45.

Insider Transactions at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Insulet Stock Performance

NASDAQ:PODD opened at $331.17 on Friday. The company has a market capitalization of $23.30 billion, a P/E ratio of 100.66, a P/E/G ratio of 2.64 and a beta of 1.39. The business has a fifty day simple moving average of $322.22 and a two-hundred day simple moving average of $314.69. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter in the prior year, the firm earned $1.08 EPS. The business’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.